NYSE Liffe lists equity options on ThromboGenics
NYSE Liffe, the Europe-based derivatives business of NYSE Euronext, has added options on the shares of ThromboGenics, a biopharmaceutical company focused on developing and commercialising ophthalmic medicines, to its range of equity option classes.
The options are available on the Brussels derivatives market of NYSE Liffe.
Vincent Van Dessel, chief executive of NYSE Euronext Brussels says: “We are pleased to announce the listing of options on ThromboGenics, a successful Belgian company and a great example of our leading role in the biotech industry niche. This listing will further enhance the visibility of the company.”
Chris Buyse, chief financial officer of ThromboGenics, says: “We are pleased with the listing of options on the shares of our company. We believe that this will offer our shareholders an alternative financial instrument on the NYSE Liffe market. This will enhance the liquidity of our share and increase the visibility of ThromboGenics in the financial world.”
These American-style options will expire on the third Friday of the expiry month and will have initial lifetimes of one to six months. Options on ThromboGenics are introduced under trading symbol THR.
Each option represents 100 shares in ThromboGenics and will be centrally cleared via LCH.Clearnet. Liquidity in the options will be supported by two market makers: All Options International and B&Btrading.
NYSE Liffe lists stock options on 278 European companies via the Amsterdam, Brussels, London and Paris central order books.
The introduction of the new option class on ThromboGenics is the first one on a Belgian biotech company.
- By Category
- News from other sites
- Special Reports
- By Location
- By Subject
Latest Special Report